

IN THE CLAIMS:

Amend claim 18 as follows, the amendments being shown by brackets and underlining in an Appendix hereto:

B1 18. (Amended) A transdermal therapeutic system comprising a self-adhesive matrix layer containing the free base (-)-5,6,7,8-tetrahydro-6-[propyl-1[2-(2-thienyl) ethyl]amino]-1-naphthalenol in an amount effective for the treatment of the symptoms of Parkinson's syndrome, wherein the matrix is based on a non-aqueous, acrylate-based or silicone-based polymer adhesive system having a solubility of $\geq 5\%$ (w/w) for the free base (-)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl) ethyl]-amino]-1-naphthalenol; a backing layer inert to the components of the matrix layer; and a protective foil or sheet covering the matrix layer to be removed prior to use.

REMARKS

The 35 U.S.C. 112, first paragraph, rejection directed to the recitation "substantially free..." has been obviated by the deletion of that recitation.